{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:37Z","timestamp":1790446957519,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Optical coherence tomography (OCT) for measuring retinal layer thicknesses is a new modality relevant for the diagnosis and prognosis of multiple sclerosis (MS), which is now anchored in clinical routine at the latest with the 2024 revision of the McDonald criteria. The aim of this consensus paper, prepared by the members of the Austrian Network for Optical Coherence Tomography in Multiple Sclerosis (AN-OCT-MS), is to provide a acomprehensive recommendation for the use of OCT in patients with MS.<\/jats:p>","DOI":"10.1007\/s00415-025-13537-8","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T17:01:21Z","timestamp":1765645281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS)"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-0851","authenticated-orcid":false,"given":"Gabriel","family":"Bsteh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Velez Escola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewald","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Traxler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Raithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Pemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Austrian Network for Optical Coherence in Multiple Sclerosis (AN-OCT-MS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"13537_CR1","unstructured":"Hemmer B (2024) Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen. DGNeurologie"},{"key":"13537_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2017","unstructured":"Montalban X, Gold R, Thompson AJ et al (2017) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J 24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler J"},{"key":"13537_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/s1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J et al (2025) Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 24:850\u2013865. https:\/\/doi.org\/10.1016\/s1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"13537_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/s1474-4422(25)00275-3","volume":"24","author":"S Saidha","year":"2025","unstructured":"Saidha S, Green AJ, Leocani L et al (2025) The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol 24:880\u2013892. https:\/\/doi.org\/10.1016\/s1474-4422(25)00275-3","journal-title":"Lancet Neurol"},{"key":"13537_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/acm.0000000000001092","volume":"91","author":"J Waggoner","year":"2016","unstructured":"Waggoner J, Carline JD, Durning SJ (2016) Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research. Acad Med 91:663\u2013668. https:\/\/doi.org\/10.1097\/acm.0000000000001092","journal-title":"Acad Med"},{"key":"13537_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Ann Neurol 58:840\u2013846. https:\/\/doi.org\/10.1002\/ana.20703","journal-title":"Ann Neurol"},{"key":"13537_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"13537_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"13537_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s1474-4422(13)70259-x","volume":"13","author":"AT Toosy","year":"2014","unstructured":"Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83\u201399. https:\/\/doi.org\/10.1016\/s1474-4422(13)70259-x","journal-title":"Lancet Neurol"},{"key":"13537_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/brain\/awz038","volume":"142","author":"F London","year":"2019","unstructured":"London F, Z\u00e9phir H, Drumez E et al (2019) Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain 142:903\u2013915. https:\/\/doi.org\/10.1093\/brain\/awz038","journal-title":"Brain"},{"key":"13537_CR11","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.1212\/wnl.0000000000006207","volume":"91","author":"WJ Brownlee","year":"2018","unstructured":"Brownlee WJ, Miszkiel KA, Tur C et al (2018) Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology 91:e1130\u2013e1134. https:\/\/doi.org\/10.1212\/wnl.0000000000006207","journal-title":"Neurology"},{"key":"13537_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009504","volume":"94","author":"J-B Davion","year":"2020","unstructured":"Davion J-B, Lopes R, Drumez \u00c9 et al (2020) Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS. Neurology 94:10.1212\/WNL.0000000000009504. https:\/\/doi.org\/10.1212\/wnl.0000000000009504","journal-title":"Neurology"},{"key":"13537_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1352458517721054","volume":"24","author":"SL Galetta","year":"2018","unstructured":"Galetta SL, Balcer LJ (2018) The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS \u2013 yes. Mult Scler J 24:121\u2013122. https:\/\/doi.org\/10.1177\/1352458517721054","journal-title":"Mult Scler J"},{"key":"13537_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.24351","volume":"77","author":"I Gabilondo","year":"2015","unstructured":"Gabilondo I, Mart\u00ednez-Lapiscina EH, Fraga-Pumar E et al (2015) Dynamics of retinal injury after acute optic neuritis. Ann Neurol 77:517\u2013528. https:\/\/doi.org\/10.1002\/ana.24351","journal-title":"Ann Neurol"},{"key":"13537_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s1474-4422(17)30278-8","volume":"16","author":"A Petzold","year":"2017","unstructured":"Petzold A, Balcer LJ, Calabresi PA et al (2017) Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 16:797\u2013812. https:\/\/doi.org\/10.1016\/s1474-4422(17)30278-8","journal-title":"Lancet Neurol"},{"key":"13537_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/s1474-4422(10)70168-x","volume":"9","author":"A Petzold","year":"2010","unstructured":"Petzold A, de Boer JF, Schippling S et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9:921\u2013932. https:\/\/doi.org\/10.1016\/s1474-4422(10)70168-x","journal-title":"Lancet Neurol"},{"key":"13537_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101988","volume":"41","author":"R Behbehani","year":"2020","unstructured":"Behbehani R, Ali A, Al-Omairah H, Rousseff RT (2020) Optimization of spectral domain optical coherence tomography and visual evoked potentials to identify unilateral optic neuritis. Mult Scler Relat Dis 41:101988. https:\/\/doi.org\/10.1016\/j.msard.2020.101988","journal-title":"Mult Scler Relat Dis"},{"key":"13537_CR18","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1212\/wnl.0000000000009832","volume":"95","author":"O Outteryck","year":"2020","unstructured":"Outteryck O, Lopes R, Drumez \u00c9 et al (2020) Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology 95:e733\u2013e744. https:\/\/doi.org\/10.1212\/wnl.0000000000009832","journal-title":"Neurology"},{"key":"13537_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1212\/wnl.0000000000009840","volume":"95","author":"P Villoslada","year":"2020","unstructured":"Villoslada P, Sanchez-Dalmau B, Galetta S (2020) Optical coherence tomography: a useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology 95:239\u2013240. https:\/\/doi.org\/10.1212\/wnl.0000000000009840","journal-title":"Neurology"},{"key":"13537_CR20","doi-asserted-by":"publisher","unstructured":"Coric D, Balk LJ, Uitdehaag BMJ, Petzold A (2017) Diagnostic accuracy of optical coherence tomography Inter-Eye Percentage Difference (IEPD) for optic neuritis in multiple sclerosis. Eur J Neurol 24:. https:\/\/doi.org\/10.1111\/ene.13443","DOI":"10.1111\/ene.13443"},{"key":"13537_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/wno.0000000000000629","volume":"38","author":"RC Nolan","year":"2018","unstructured":"Nolan RC, Galetta SL, Frohman TC et al (2018) Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis. J Neuro-Ophthalmol 38:451\u2013458. https:\/\/doi.org\/10.1097\/wno.0000000000000629","journal-title":"J Neuro-Ophthalmol"},{"key":"13537_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327468","author":"JN Bijvank","year":"2021","unstructured":"Bijvank JN, Uitdehaag BMJ, Petzold A (2021) Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2021-327468","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13537_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102403","author":"G Bsteh","year":"2020","unstructured":"Bsteh G, Hegen H, Altmann P et al (2020) Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2020.102403","journal-title":"Mult Scler Relat Disord"},{"key":"13537_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207507.10.1212\/wnl.0000000000207507","author":"G Bsteh","year":"2023","unstructured":"Bsteh G, Hegen H, Altmann P et al (2023) Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for MS. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207507.10.1212\/wnl.0000000000207507","journal-title":"Neurology"},{"key":"13537_CR25","doi-asserted-by":"publisher","unstructured":"Vidal-Jordana A, Rovira A, Calderon W, et al (2023) Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. Neurology 102:. https:\/\/doi.org\/10.1212\/wnl.0000000000207805","DOI":"10.1212\/wnl.0000000000207805"},{"key":"13537_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000207913","volume":"102","author":"S Galetta","year":"2024","unstructured":"Galetta S, Brownlee W (2024) Assignment completed: the optic nerve should graduate to be the fifth lesion site for the diagnosis of multiple sclerosis. Neurology 102:e207913. https:\/\/doi.org\/10.1212\/wnl.0000000000207913","journal-title":"Neurology"},{"key":"13537_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22:78\u201388. https:\/\/doi.org\/10.1016\/s1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"key":"13537_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01473-3","author":"D Jakimovski","year":"2023","unstructured":"Jakimovski D, Bittner S, Zivadinov R et al (2023) Multiple sclerosis. Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(23)01473-3","journal-title":"Lancet"},{"key":"13537_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/s1474-4422(16)00068-5","volume":"15","author":"EH Mart\u00ednez-Lapiscina","year":"2016","unstructured":"Mart\u00ednez-Lapiscina EH, Arnow S, Wilson JA et al (2016) Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol 15:574\u2013584. https:\/\/doi.org\/10.1016\/s1474-4422(16)00068-5","journal-title":"Lancet Neurol"},{"key":"13537_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517740216","author":"G Bsteh","year":"2017","unstructured":"Bsteh G, Hegen H, Teuchner B et al (2017) Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458517740216","journal-title":"Mult Scler J"},{"key":"13537_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15681","author":"J Wauschkuhn","year":"2023","unstructured":"Wauschkuhn J, Solorza BG, Aly L et al (2023) Retinal ganglion cell loss is associated with future disability worsening in early relapsing\u2013remitting multiple sclerosis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15681","journal-title":"Eur J Neurol"},{"key":"13537_CR32","doi-asserted-by":"publisher","unstructured":"Alba-Arbalat S, Solana E, Lopez-Soley E, et al (2023) Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis. J Neurol Neurosurg Psychiatry jnnp-2023\u2013332332. https:\/\/doi.org\/10.1136\/jnnp-2023-332332","DOI":"10.1136\/jnnp-2023-332332"},{"key":"13537_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15718","author":"G Bsteh","year":"2023","unstructured":"Bsteh G, Hegen H, Altmann P et al (2023) Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15718","journal-title":"Eur J Neurol"},{"key":"13537_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1212\/con.0000000000000768","volume":"25","author":"JL Bennett","year":"2019","unstructured":"Bennett JL (2019) Optic neuritis. Continuum 25:1236\u20131264. https:\/\/doi.org\/10.1212\/con.0000000000000768","journal-title":"Continuum"},{"key":"13537_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000200970","volume":"99","author":"G Bsteh","year":"2022","unstructured":"Bsteh G, Krajnc N, Riedl K et al (2022) Retinal layer thinning after optic neuritis is associated with future relapse remission in relapsing multiple sclerosis. Neurology 99:10.1212\/WNL.0000000000200970. https:\/\/doi.org\/10.1212\/wnl.0000000000200970","journal-title":"Neurology"},{"key":"13537_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","volume":"67","author":"LS Talman","year":"2010","unstructured":"Talman LS, Bisker ER, Sackel DJ et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67:749\u2013760. https:\/\/doi.org\/10.1002\/ana.22005","journal-title":"Ann Neurol"},{"key":"13537_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/wnl.0b013e31827b1a1c","volume":"80","author":"JN Ratchford","year":"2013","unstructured":"Ratchford JN, Saidha S, Sotirchos ES et al (2013) Active MS is associated with accelerated retinal ganglion cell\/inner plexiform layer thinning. Neurology 80:47\u201354. https:\/\/doi.org\/10.1212\/wnl.0b013e31827b1a1c","journal-title":"Neurology"},{"key":"13537_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.24487","volume":"78","author":"S Saidha","year":"2015","unstructured":"Saidha S, Al-Louzi O, Ratchford JN et al (2015) Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol 78:801\u2013813. https:\/\/doi.org\/10.1002\/ana.24487","journal-title":"Ann Neurol"},{"key":"13537_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/wnl.0000000000003582","volume":"88","author":"J Button","year":"2017","unstructured":"Button J, Al-Louzi O, Lang A et al (2017) Disease-modifying therapies modulate retinal atrophy in multiple sclerosis. Neurology 88:525\u2013532. https:\/\/doi.org\/10.1212\/wnl.0000000000003582","journal-title":"Neurology"},{"key":"13537_CR40","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1212\/wnl.0000000000004736","volume":"89","author":"M Pisa","year":"2017","unstructured":"Pisa M, Guerrieri S, Maggio GD et al (2017) No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. Neurology 89:2469\u20132475. https:\/\/doi.org\/10.1212\/wnl.0000000000004736","journal-title":"Neurology"},{"key":"13537_CR41","unstructured":"Coric D, Uitdehaag B, Petzold A, Balk LJ (2018) Annualized inner retinal layer atrophy rates show a flooring effect in longstanding MS; a limitation for longitudinal OCT studies"},{"key":"13537_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/ene.13897","volume":"26","author":"G Bsteh","year":"2019","unstructured":"Bsteh G, Hegen H, Teuchner B et al (2019) Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing\u2013remitting multiple sclerosis. Eur J Neurol 26:865\u2013871. https:\/\/doi.org\/10.1111\/ene.13897","journal-title":"Eur J Neurol"},{"key":"13537_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/eb.s295610","volume":"13","author":"N Schurz","year":"2021","unstructured":"Schurz N, Sariaslani L, Altmann P et al (2021) Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort. Eye Brain 13:59\u201369. https:\/\/doi.org\/10.2147\/eb.s295610","journal-title":"Eye Brain"},{"key":"13537_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520935724","author":"G Bsteh","year":"2020","unstructured":"Bsteh G, Berek K, Hegen H et al (2020) Macular ganglion cell\u2013inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458520935724","journal-title":"Mult Scler J"},{"key":"13537_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14829","author":"G Bsteh","year":"2021","unstructured":"Bsteh G, Hegen H, Altmann P et al (2021) Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.14829","journal-title":"Eur J Neurol"},{"key":"13537_CR46","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000971","author":"Y You","year":"2021","unstructured":"You Y, Barnett MH, Yiannikas C et al (2021) Interferon-\u03b2 is less effective than other drugs in controlling the rate of retinal ganglion cell loss in MS. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000971","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13537_CR47","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00415-022-11535-8","volume":"270","author":"A Cagol","year":"2023","unstructured":"Cagol A, Fuertes NC, Stoessel M et al (2023) Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis. J Neurol 270:2139\u20132148. https:\/\/doi.org\/10.1007\/s00415-022-11535-8","journal-title":"J Neurol"},{"key":"13537_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214069","volume":"105","author":"G Bsteh","year":"2025","unstructured":"Bsteh G, Hegen H, Krajnc N et al (2025) Association between retinal layer atrophy with clinical and radiologic progression in people with relapsing multiple sclerosis. Neurology 105:e214069. https:\/\/doi.org\/10.1212\/wnl.0000000000214069","journal-title":"Neurology"},{"key":"13537_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/wno.0000000000000802","volume":"40","author":"JK Chan","year":"2020","unstructured":"Chan JK, de Lapiscina EHM, Taylor C et al (2020) Long-term stability of neuroaxonal structure in Alemtuzumab-treated relapsing-remitting multiple sclerosis patients. J Neuro-ophthalmol 40:37\u201343. https:\/\/doi.org\/10.1097\/wno.0000000000000802","journal-title":"J Neuro-ophthalmol"},{"key":"13537_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/eme07030","volume":"7","author":"FD Angelis","year":"2020","unstructured":"Angelis FD, Connick P, Parker RA et al (2020) Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy Mech Eval 7:1\u201372. https:\/\/doi.org\/10.3310\/eme07030","journal-title":"Efficacy Mech Eval"},{"key":"13537_CR51","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/wnl.0000000000207551","volume":"101","author":"H Ehrhardt","year":"2023","unstructured":"Ehrhardt H, Lambe J, Moussa H et al (2023) Effects of Ibudilast on retinal atrophy in progressive multiple sclerosis subtypes: post hoc analyses of the SPRINT-MS trial. Neurology 101:e1014\u2013e1024. https:\/\/doi.org\/10.1212\/wnl.0000000000207551","journal-title":"Neurology"},{"key":"13537_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241267257","author":"G Bsteh","year":"2024","unstructured":"Bsteh G, Hegen H, Krajnc N et al (2024) Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-evidence for applying a rebaselining concept. Mult Scler J. https:\/\/doi.org\/10.1177\/13524585241267257","journal-title":"Mult Scler J"},{"key":"13537_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, Balk L, Costello F et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 7:e34823. https:\/\/doi.org\/10.1371\/journal.pone.0034823","journal-title":"PLoS ONE"},{"key":"13537_CR54","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3341\/jkos.2019.60.5.434","volume":"60","author":"SY Cho","year":"2019","unstructured":"Cho SY, Hwang YH (2019) Comparison of macular retinal thickness among four optical coherence tomography devices in healthy young subjects. J Korean Ophthalmol Soc 60:434\u2013439. https:\/\/doi.org\/10.3341\/jkos.2019.60.5.434","journal-title":"J Korean Ophthalmol Soc"},{"key":"13537_CR55","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41598-024-54109-6","volume":"14","author":"KT Nam","year":"2024","unstructured":"Nam KT, Yun C, Seo M et al (2024) Comparison of retinal thickness measurements among four different optical coherence tomography devices. Sci Rep 14:3560. https:\/\/doi.org\/10.1038\/s41598-024-54109-6","journal-title":"Sci Rep"},{"key":"13537_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022947","volume":"6","author":"CV Warner","year":"2011","unstructured":"Warner CV, Syc SB, Stankiewicz AM et al (2011) The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS ONE 6:e22947. https:\/\/doi.org\/10.1371\/journal.pone.0022947","journal-title":"PLoS ONE"},{"key":"13537_CR57","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1167\/iovs.10-6643","volume":"52","author":"E Garcia-Martin","year":"2011","unstructured":"Garcia-Martin E, Pueyo V, Pinilla I et al (2011) Fourier-domain OCT in multiple sclerosis patients: reproducibility and ability to detect retinal nerve fiber layer atrophy. Investig Ophthalmol Vis Sci 52:4124\u20134131. https:\/\/doi.org\/10.1167\/iovs.10-6643","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13537-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13537-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13537-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:58:19Z","timestamp":1773665899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13537-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13537"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13537-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gabriel Bsteh\n                      has participated in meetings sponsored by, received speaker honoraria, or travel funding from Biogen, BMS, Heidelberg Engineering, Janssen, Lilly, Medwhizz, Merck, Neuraxpharm, Novartis, Roche, Sanofi, Teva, and Zeiss, and received honoraria for consulting Adivo Associates, Biogen, BMS, Janssen, Merck, Novartis, Roche, Sanofi, and Teva. He has received unrestricted research grants from BMS and Novartis. He serves on the Executive Committee of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Board of Directors of the International Multiple Sclerosis VisualSystem Consortium (IMSVISUAL).\n                      Luisa Velez Escola\n                      has participated in meetings sponsored by Chiesi.\n                      Harald Hegen\n                      has participated in meetings sponsored by, received speaker honoraria, or travel funding from Bayer, Biogen, Bristol Myers Squibb, Horizon, Janssen, Merck, Novartis, Sanofi-Genzyme, Siemens, and Teva, and received honoraria for acting as consultant for Biogen, Bristol Myers Squibb, Novartis, Roche, Sanofi-Genzyme, and Teva.\n                      Ewald Lindner\n                      has received honoraria for speaking and consulting from iStar, Zeiss, Santen, Abbvie, and Alcon.\n                      Michael Khalil\n                      has received travel funding and speaker honoraria from Bayer, Novartis, Merck, Biogen, Sanofi, and Teva Pharmaceutical Industries Ltd. and serves on scientific advisory boards for Biogen, Merck, Roche, Novartis, Bristol-Myers Squibb, and Gilead. He received research grants from Teva Pharmaceutical Industries, Ltd., Biogen, and Novartis.\n                      Sophie Schneider\n                      has received speaker honoraria from Janssen-Cilag.\n                      Gerhard Traxler\n                      has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations), or travel funding from Alexion, Biogen, Celgene\/BMS, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva.\n                      Erich Raithel\n                      has received honoraria for speaking and consulting from Heidelberg Engineering and Zeiss.\n                      Christian Bsteh\n                      has received honoraria for consulting and fundings to attend congresses by Biogen, Janssen, Merck, Novartis, Roche, and Sanofi-Genzyme.\n                      Christoph Mitsch\n                      nothing to disclose.\n                      Thomas Berger\n                      has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Bayer, Biogen, Bionorica, BMS\/Celgene, Genesis, GSK, GW\/Jazz Pharma, Horizon, Janssen-Cilag, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva, and UCB. His institution has received financial support in the past 12\u00a0months by unrestricted research grants (Biogen, Bayer, BMS\/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme, and Teva.\n                      Berthold Pemp\n                      has received honoraria for speaking and consulting from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"24"}}